Medtronic announced second-quarter results for its 2025 fiscal year. Here are three things to know:

Continued momentum

Our innovative therapies are driving consistent growth. We reported a mid-single-digit increase in organic revenue for the eighth consecutive quarter, results helped by strong sales of products that treat conditions ranging from heart disease to chronic pain.

More innovation to come

Each of our businesses continues to invest in new therapies to reach more patients. And we expect to sustain our growth given the strength of our pipeline in high-impact markets like pulsed field ablation (PFA), which treats atrial fibrillation, surgical robotics, and hypertension.

Raising our guidance

Following our continued strong performance, we raised our guidance for the full 2025 fiscal year. We now expect organic revenue growth of 4.75% to 5%, and non-GAAP diluted earnings per share of $5.44 to $5.50.

L009-11182024 

Related content

Technology bias is real. Here’s what we’re doing to fix it

When health tech meets ethical hacking

An engineer and the earthworms that revolutionized spinal cord stimulation